<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="healthcare" lang="en"><front><journal-meta><journal-id journal-id-type="publisher">IJCRR</journal-id><journal-id journal-id-type="nlm-ta">I Journ Cur Res Re</journal-id><journal-title-group><journal-title>International Journal of Current Research and Review</journal-title><abbrev-journal-title abbrev-type="pubmed">I Journ Cur Res Re</abbrev-journal-title></journal-title-group><issn pub-type="ppub">2231-2196</issn><issn pub-type="opub">0975-5241</issn><publisher><publisher-name>Radiance Research Academy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">4544</article-id><article-id pub-id-type="doi"/><article-id pub-id-type="doi-url"> https://doi.org/10.31782/IJCRR.2022.141308</article-id><article-categories><subj-group subj-group-type="heading"><subject>Healthcare</subject></subj-group></article-categories><title-group><article-title>&#13;
	Respiratory Morbidities and Neurodevelopmental Outcome in Preterm Infants of Mother Exposed to Antenatal Corticosteroids&#13;
&#13;
&#13;
&#13;
	__ampersandsignnbsp;&#13;
&#13;
&#13;
&#13;
	__ampersandsignnbsp;&#13;
&#13;
&#13;
&#13;
	__ampersandsignnbsp;&#13;
&#13;
</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jahan</surname><given-names>Mosammad Alpana</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sultana</surname><given-names>Rabeya</given-names></name></contrib><contrib contrib-type="author"><name><surname>Roy</surname><given-names>Tarun Kumar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dey</surname><given-names>Sanjoy Kumer</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mannan</surname><given-names>M. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shabuj</surname><given-names>Mohammad Kamrul Hassan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Jahan</surname><given-names>Ismat</given-names></name></contrib><contrib contrib-type="author"><name><surname>Moni</surname><given-names>Sadeka Choudhury</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shahidullah</surname><given-names>Mohammod</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><day>5</day><month>07</month><year>2022</year></pub-date><volume>3)</volume><issue/><fpage>43</fpage><lpage>51</lpage><permissions><copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p></license></permissions><abstract><p>&#13;
	Introduction: Each year, about 15 million babies are born preterm, and 1 million babies die due to complications of preterm birth. Antenatal corticosteroid is one of the most effective evidence-based interventions that can reduce mortality and morbidity in preterm newborns. Objective: The purpose of this study was to evaluate the effect of antenatal corticosteroids on respiratory morbidities and neurodevelopmental outcomes among preterm neonates. Methodology: This prospective cohort study included admitted premature infant__ampersandsignrsquo;s __ampersandsignle; 34 weeks. Infant__ampersandsignrsquo;s baseline demographics and maternal history of complete ACS exposure or no exposure were evaluated. The development of respiratory morbidities with support was compared between two groups during the neonatal period. After discharge from the NICU, neonates were followed up to assess neurodevelopment at 3rd and 6th months of age using Bayley Scales of Infant Development (BSID-III). Analysis was done to see the relationship with ACS exposure. Results: A total of 82 neonates were enrolled. Among them, 44 neonates in the ACS exposed group and 38 in the ACS unexposed group were assessed for the development of respiratory morbidity. Only 9(20.5%) in the ACS exposed group and 28 (73.7%) in the ACS unexposed group developed respiratory morbidities. Respiratory support with duration was also needed more in the ACS unexposed group. Neurodevelopmental assessment at 3 months was significantly lower in all three domains between the ACS exposed and unexposed groups: cognition (81.67__ampersandsignplusmn;7.58 vs. 73.50__ampersandsignplusmn;10.16: p-__ampersandsignlt;0.001), motor (84.50__ampersandsignplusmn;9.83 vs. 76.83__ampersandsignplusmn;12.03, p-0.013) and language (84.67__ampersandsignplusmn;6.33 vs.77.88__ampersandsignplusmn;9.98, p-0.004) respectively. At 6 months, motor and language scores improved, though cognition was low in both groups. In univariate analysis, ACS exposure was found to be a significant factor in relation to normal neurodevelopment. Conclusion: Antenatal corticosteroid therapy effectively reduces respiratory morbidities in preterm neonates born __ampersandsignle; 34 weeks of gestation. ACS exposure was also associated with improved neurodevelopmental outcome.&#13;
&#13;
</p></abstract><kwd-group><kwd>Neonatal period</kwd><kwd> Neurodevelopmental Outcome</kwd><kwd> Respiratory morbidity</kwd><kwd> Antenatal Corticosteroids</kwd><kwd> Antenatal Corticosteroid Therapy</kwd><kwd> Univariate Analysis</kwd></kwd-group></article-meta></front></article>
